Paper Details

  1. Home
  2. Paper Details

Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.

Author: DillonMairead, HannaDesirae, HuckabeeJordan B, KennedyErin, LeBlancThomas W, LiZhiguo, RogersElizabeth, WhiteOlivia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Posaconazole is the recommended prophylactic agent for invasive fungal infections (IFIs) in patients with acute myeloid leukemia (AML) during induction chemotherapy. However, it is associated with QTc prolongation, hepatotoxicity, and drug-drug interactions. The role of isavuconazole as an alternative to posaconazole in this setting is uncertain due to conflicting evidence.
Paper Details　
Original Abstract of the Article :
Invasive fungal infection (IFI) prophylaxis is recommended in patients with acute myeloid leukemia (AML) during induction chemotherapy. Posaconazole (POSA) is the recommended agent of choice; however, this medication can be associated with QTc prolongation, hepatotoxicity, and drug-drug interactions...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/10781552231175825

データ提供：米国国立医学図書館（NLM）

Isavuconazonium: A Promising Alternative for Antifungal Prophylaxis in AML

Invasive fungal infections (IFI) pose a significant threat to patients with acute myeloid leukemia (AML) during induction chemotherapy. Posaconazole (POSA) is the current standard of care for IFI prophylaxis but can be associated with adverse effects like QTc prolongation, hepatotoxicity, and drug-drug interactions. This article explores the potential of isavuconazonium (ISAV) as an alternative to POSA for IFI prophylaxis in AML. The authors highlight the need for further research to definitively establish the role of ISAV in this setting.

Isavuconazonium: A Potential Solution for a Challenging Problem

This article highlights the need for safer and more effective treatment options for preventing invasive fungal infections in patients with acute myeloid leukemia (AML). While POSA is the current standard of care, it can cause significant adverse effects. The authors suggest that isavuconazonium (ISAV) may offer a promising alternative but emphasize the need for further research to confirm its efficacy and safety in this setting.

Isavuconazonium: A New Path in the Fight Against Fungal Infections

Like a new path through a desert, ISAV offers a potential alternative to POSA for preventing invasive fungal infections in patients with acute myeloid leukemia (AML). This article highlights the need for further research to evaluate the efficacy and safety of ISAV in this challenging setting, potentially offering a safer and more effective treatment option for patients.

Dr. Camel's Conclusion

This article highlights the ongoing quest to find safer and more effective treatment options for patients with acute myeloid leukemia (AML) who are at risk of developing invasive fungal infections. While posaconazole is the current standard of care, isavuconazonium (ISAV) offers a potential alternative. Further research is needed to definitively establish the role of ISAV in this setting, but it holds promise for improving patient outcomes.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-05-25
Further Info :

Pubmed ID

37186784

DOI: Digital Object Identifier

10.1177/10781552231175825

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.